DFD 06

Drug Profile

DFD 06

Alternative Names: DFD-06

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promius Pharma
  • Class Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 22 Aug 2017 DFD 06 licensed to Encore Dermatology in USA
  • 02 May 2017 Phase-II clinical trials in Plaque psoriasis (In children, In adolescents) in USA (Topical) (NCT03179605)
  • 01 Jul 2016 Promius Pharma completes a phase II trial in Plaque psoriasis in USA (NCT02131324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top